Maxcyte Inc (MXCT) Stock Price, Quote & News

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applicatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 301 944 1700

Website: www.maxcyte.com

Address:

9713 Key West Avenue, Suite 400, Rockville, United States

MarketBeat May. 13 at 1:10 AM

https://marketbeat.com/a/8651183/ $MXCT MaxCyte Q1 Earnings Call Highlights

0 · Reply

burbs88 May. 12 at 10:48 PM

$MXCT Go ahead and run sweetheart

0 · Reply

Kazooper May. 12 at 9:52 PM

$MXCT @BeefStewart wake up buddy

0 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-maxcyte-inc-stock/ $MXCT MaxCyte Earnings Transcript

0 · Reply

Usually_Im_Right May. 12 at 9:31 PM

$MXCT like i said couple hours ago… getting close

0 · Reply

Mindegap May. 12 at 8:20 PM

$MXCT authorized a $10M buyback and says it expects to use most of it soon. That’s the opposite direction of dilution.

2 · Reply

StocktwitsEarnings May. 12 at 8:19 PM

$MXCT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 60.00% YoY • Reported revenue of $9.65M down -7.11% YoY • MaxCyte reiterates full year 2026 revenue guidance of $30M, comprising $25M from Core revenue and $5M from Strategic Platform License Program-related revenue.

0 · Reply

Usually_Im_Right May. 12 at 6:50 PM

$MXCT $1+ coming?

1 · Reply

Mindegap May. 1 at 5:50 PM

$MXCT Hmmm...looks like slow and steady accumulation. They work with: $CRSP $ALLO $CRBU and others.

0 · Reply

StockConsultant Apr. 28 at 12:15 PM

$MXCT MaxCyte stock, watch for a bottom breakout at https://stockconsultant.com/?MXCT

0 · Reply

MaxCyte reports Q1 EPS (4c), consensus (9c)

2026-05-12T21:20:35.000Z - 14 hours ago

MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M

May 12, 2026, 4:30 PM EDT - 15 hours ago

MaxCyte Earnings Call Transcript: Q1 2026

May 12, 2026, 4:05 PM EDT - 16 hours ago

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

Apr 29, 2026, 4:05 PM EDT - 13 days ago

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-25T13:41:55.000Z - 6 weeks ago

MaxCyte price target lowered to $5 from $7 at Craig-Hallum

Mar 24, 2026, 4:30 PM EDT - 7 weeks ago

MaxCyte Earnings Call Transcript: Q4 2025

2026-03-24T20:22:34.000Z - 7 weeks ago

MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M

2026-03-24T20:16:47.000Z - 7 weeks ago

MaxCyte reports Q4 EPS (9c), consensus (8c)

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

2026-03-23T12:20:40.000Z - 7 weeks ago

MaxCyte appoints Parmeet Ahuja as CFO

Mar 23, 2026, 8:05 AM EDT - 7 weeks ago

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

2026-02-24T13:37:10.000Z - 2 months ago

MaxCyte announced the launch of ExPERT DTx

Feb 24, 2026, 8:05 AM EST - 2 months ago

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

Feb 23, 2026, 4:05 PM EST - 2 months ago

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

2026-01-12T13:15:35.000Z - 4 months ago

MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M

Jan 12, 2026, 8:05 AM EST - 4 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

2025-12-02T18:55:28.000Z - 5 months ago

MaxCyte management to meet with Craig-Hallum

Dec 1, 2025, 9:00 AM EST - 5 months ago

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Nov 19, 2025, 9:00 AM EST - 6 months ago

MaxCyte Transcript: Stephens Annual Investment Conference

2025-11-12T22:20:36.000Z - 6 months ago

MaxCyte CFO Douglas Swirsky to transition out of role

2025-11-12T22:05:49.000Z - 6 months ago

MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year

2025-11-12T21:55:21.000Z - 6 months ago

MaxCyte reports Q3 EPS (12c), consensus (9c)

Nov 12, 2025, 4:30 PM EST - 6 months ago

MaxCyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:08 PM EST - 6 months ago

MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:05 PM EST - 6 months ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

2025-11-05T13:16:57.000Z - 6 months ago

MaxCyte reiterates 2025 revenue guidance

2025-11-05T13:10:23.000Z - 6 months ago

MaxCyte reports preliminary Q3 revenue $6.8M, consensus $8.37M

Nov 5, 2025, 8:05 AM EST - 6 months ago

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Oct 8, 2025, 8:05 AM EDT - 7 months ago

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

2025-10-06T12:36:36.000Z - 7 months ago

MaxCyte enters platform license agreement with Moonlight Bio

Oct 6, 2025, 8:05 AM EDT - 7 months ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

Sep 22, 2025, 4:30 PM EDT - 8 months ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2025-08-11T10:10:09.000Z - 9 months ago

MaxCyte downgraded to Neutral from Buy at BTIG

2025-08-07T08:50:13.000Z - 9 months ago

MaxCyte downgraded to Market Perform from Outperform at William Blair

2025-08-06T21:11:47.000Z - 9 months ago

MaxCyte reports Q2 EPS (12c), consensus (10c)

2025-08-06T21:11:25.000Z - 9 months ago

MaxCyte sees FY25 core revenue flat to down 10%

Aug 6, 2025, 4:30 PM EDT - 9 months ago

MaxCyte Earnings Call Transcript: Q2 2025

2025-08-04T12:21:57.000Z - 10 months ago

MaxCyte signs platform license agreement with Adicet Bio

Aug 4, 2025, 8:05 AM EDT - 10 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

Jul 31, 2025, 8:05 AM EDT - 10 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Jul 9, 2025, 8:05 AM EDT - 11 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 1, 2025, 1:00 AM EDT - 11 months ago

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

Jun 11, 2025, 2:00 AM EDT - 1 year ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

May 7, 2025, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

Apr 10, 2025, 2:00 AM EDT - 1 year ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 11, 2025, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Mar 3, 2025, 10:30 AM EST - 1 year ago

MaxCyte Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 2:00 AM EST - 1 year ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 7, 2025, 2:00 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Jan 30, 2025, 2:00 AM EST - 1 year ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 13, 2025, 3:05 AM EST - 1 year ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 9, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Nov 19, 2024, 4:00 PM EST - 1 year ago

MaxCyte Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 18, 2024, 10:55 AM EST - 1 year ago

MaxCyte Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 8:05 AM EST - 1 year ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 6, 2024, 4:30 PM EST - 1 year ago

MaxCyte Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 11, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Sep 16, 2024, 2:00 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 5, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Aug 6, 2024, 4:30 PM EDT - 1 year ago

MaxCyte Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Jul 9, 2024, 4:05 PM EDT - 2 years ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 5, 2024, 3:40 PM EDT - 2 years ago

MaxCyte Transcript: The 44th Annual William Blair Growth Stock Conference

May 29, 2024, 8:05 AM EDT - 2 years ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 22, 2024, 8:05 AM EDT - 2 years ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 7, 2024, 4:30 PM EDT - 2 years ago

MaxCyte Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

Apr 10, 2024, 8:05 AM EDT - 2 years ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 8:05 AM EDT - 2 years ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Mar 12, 2024, 4:30 PM EDT - 2 years ago

MaxCyte Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:05 PM EDT - 2 years ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Mar 5, 2024, 9:10 AM EST - 2 years ago

MaxCyte Transcript: TD Cowen 44th Annual Health Care Conference

Mar 4, 2024, 4:05 PM EST - 2 years ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

Feb 9, 2024, 8:05 AM EST - 2 years ago

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

Jan 30, 2024, 8:05 AM EST - 2 years ago

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Jan 23, 2024, 8:05 AM EST - 2 years ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

MarketBeat May. 13 at 1:10 AM

https://marketbeat.com/a/8651183/ $MXCT MaxCyte Q1 Earnings Call Highlights

0 · Reply

burbs88 May. 12 at 10:48 PM

$MXCT Go ahead and run sweetheart

0 · Reply

Kazooper May. 12 at 9:52 PM

$MXCT @BeefStewart wake up buddy

0 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-maxcyte-inc-stock/ $MXCT MaxCyte Earnings Transcript

0 · Reply

Usually_Im_Right May. 12 at 9:31 PM

$MXCT like i said couple hours ago… getting close

0 · Reply

Mindegap May. 12 at 8:20 PM

$MXCT authorized a $10M buyback and says it expects to use most of it soon. That’s the opposite direction of dilution.

2 · Reply

StocktwitsEarnings May. 12 at 8:19 PM

0 · Reply

Usually_Im_Right May. 12 at 6:50 PM

$MXCT $1+ coming?

1 · Reply

Mindegap May. 1 at 5:50 PM

$MXCT Hmmm...looks like slow and steady accumulation. They work with: $CRSP $ALLO $CRBU and others.

0 · Reply

StockConsultant Apr. 28 at 12:15 PM

$MXCT MaxCyte stock, watch for a bottom breakout at https://stockconsultant.com/?MXCT

0 · Reply

pleasemoney Apr. 22 at 2:05 PM

$MXCT

0 · Reply

Mindegap Apr. 20 at 7:50 PM

If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT

1 · Reply

OfficialStocktwitsUser Apr. 17 at 11:22 PM

$MXCT RSI: 70.90, MACD: 0.0120 Vol: 0.06, MA20: 0.76, MA50: 0.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Apr. 17 at 8:15 PM

$MXCT Share Price: $0.85 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.11 – $0.14 Target Zone: $0.19 – $0.23 Potential Upside: 55% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

burbs88 Apr. 15 at 1:27 PM

$MXCT I'm going to go ahead and take a nibble here.

0 · Reply

Mindegap Apr. 14 at 2:19 PM

$MXCT Can help all MaxCyte customers. Today, the FDA issued a draft guidance that when finalized, will provide recommendations for standardized methods for sponsors developing human gene therapy products that incorporate genome editing technologies. https://fda.gov/news-events/press-announcements/fda-issues-draft-guidance-genome-editing-safety-standards-advance-gene-therapy-development

0 · Reply

Mindegap Apr. 13 at 1:23 PM

$MXCT $ALLO had great results this morning. They use $MXCT tech.

0 · Reply

Hertha Apr. 13 at 1:07 AM

$MXCT The platform is already embedded at the regulated cell-engineering layer through clinical and commercial licensing, FDA Master File, and documented methodology-switching burden, across 31 active SPL partnerships with one commercial and 13 clinical programs.

0 · Reply

noccers Apr. 10 at 6:22 AM

$MXCT Hammer time.

0 · Reply

PSM_EmpowerTrading Apr. 9 at 1:27 PM

🌅 Watchlist part 3 ✅ $ALBT .50 support, if above .70, has potential to .80/1.00 ✅ $UCAR 2.20 support, if above 2.60, has potential to 2.80/3.30 ✅ $VEEE .20 support, if above .30, has potential to .40/.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵

0 · Reply

PSM_EmpowerTrading Apr. 9 at 5:04 AM

🌅 Watchlist part 2 ✅ $ARAI .70 support, if above 1, has potential to 1.20/1.30 ✅ $UCAR 3.0 support, if above 3.50, has potential to 3.80/3.90 ✅ $VEEE .30 support, if above .40, has potential to .50/.55 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GREEN, not GREED

0 · Reply

PSM_EmpowerTrading Apr. 8 at 1:26 PM

🌅 Watchlist part 3 ✅ $IRIX 1.05 support, if above 1.30, have potential to 1.50/.70 ✅ $WGRX .10 support, if above .20, have potential to .30/.40 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $MXCT $NNOX still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D.

0 · Reply

Market Cap	87.51M
Revenue (ttm)	33.03M
Net Income (ttm)	-44.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-135.12%
Debt to Equity Ratio	0.00

Volume	766,500
Avg Vol	822,310
Day's Range	N/A - N/A
Shares Out	107.12M
Stochastic %K	36%
Beta	1.37
Analysts	Strong Sell
Price Target	$4.67